Ad5-nCoV COVID-19 Vaccine is Safe and Efficacious
A phase 3 trial shows one dose is 91.7 % effective against severe disease.
mRNA COVID-19 Vaccine Efficacy Against Infection or Death in an At-Risk Study Group
A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.
President Biden Announces Additional COVID-19 Plans
The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.
Moderna COVID-19 Vaccine Boosters May Provide Significant Omicron Antibodies
Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.
Navigating COVID-19 During the Holiday Season
Planning travel and social gatherings as Omicron gathers steam requires extra preparation and a degree of flexibility.
Pfizer-BioNTech Testing 3 Doses to Boost Vaccine Efficacy in Children Under 5
Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.
CDC Recommends mRNA COVID-19 Vaccines Over J&J, Citing Rare Blood Clots
The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.
Do Concurrent Vaccines Influence Future Behaviors?
Side effects that occur during concurrent vaccine administrations can influence future vaccine decisions.
Sticking It to COVID-19: The Expansion of the Pfizer-BioNTech Vaccine EUA
A review of the data and circumstances that led to authorization in children ages 5 to 11 years.
Mixing 2-Dose Primary COVID-19 Vaccines Can Increase Access While Preserving Protection
Clinical trial compares immunogenicity of mixing mRNA, adenoviral and spike-adjuvant vaccines in 2-dose series against COVID-19.
COVID-19: Year 2 in Review
A reflection on the wins and setbacks in the second year of our pandemic, 2021.
Booster Dose Reduced COVID-19 Across Adult Age Groups in Israel
A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.
Moderna Provides Stronger, Durable Vaccine Efficacy Over 4 Months
New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.
COVID-19 Booster Reduces Delta Variant Mortality by 90%
An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.
FDA Authorizes Pfizer-BioNTech Booster Shots for 16- and 17-Year-Olds
Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.
Pfizer and BioNTech Says Lab Tests Show 3 Doses of COVID-19 Vaccine Shows Significant Protection Against Omicron
Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.
Six Different COVID-19 Boosters Effective for AstraZeneca or Pfizer-BioNTech Recipients
A study released tonight found 6 COVID-19 booster shots increased immunity for individuals who received a full 2 doses of the AstraZeneca or Pfizer-BioNTech vaccines.
Biden Administration Has 9-Point Plan to Combat Omicron
The strategies address booster doses, travel, and rapid response.
The Latest on Omicron
As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.
As the World Works to Understand Omicron, Cases Increase Internationally and Vaccine Manufacturers Weigh In
Moderna and Pfizer's CEOs voice doubt on the current vaccines’ efficacy with the new variant, but are developing prophylaxis vaccines and treatment strategies to curtail the new strain.
First Real-World Study of BBV152 Vaccine against Symptomatic COVID-19 in India
In its first real-world study, 2 doses of India’s BBV152 vaccine offered 50% protection against symptomatic COVID-19.
Fewer Children Were Up to Date on Routine Vaccinations in 2020 than in 2019
Routine infant, child, and adolescent vaccination rates and coverage were lower in 2020 than in 2019, particularly for Black children.
Advisory Committee Recommends CDC Approve COVID-19 Booster Doses for All Adults
Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.
FDA Authorizes Pfizer-BioNTech and Moderna Booster Vaccines for All Adults
The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.
Separate Stage 3 Trials Show AstraZeneca’s COVID-19 Vaccine AZD7442 Highly Effective
AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.
FDA May Authorize Pfizer-BioNTech COVID-19 Booster for All Adults This Week
A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.
COVID-19 Cellular Immunity Persists at Least 6 Months after mRNA Vaccination
Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.
Public Health Watch: Risk of CVST Following Receipt of J&J COVID-19 Vaccine Rare
Just 39 cases among more than 2.2 million doses administered.
Phase 3 Data Finds India’s BBV152 COVID-19 Vaccine Safe and Effective
2 doses of the India-developed vaccine BBV152 offer 77.8% protection against symptomatic COVID-19 disease.
Pfizer-BioNTech Submit Request for EUA for COVID-19 Booster Doses for All Adults
Pfizer-BioNTech's request for the Emergency Use Authorization (EUA) will apply to everyone 18 years and older.
2 Clarke Drive Cranbury, NJ 08512